Free Trial
→ I was right about SpaceX (From Brownstone Research) (Ad)tc pixel Free GSK Stock Alerts

GSK (GSK) Stock Forecast & Price Target

GSK logo
GBX 1,876.62 +1.62 (+0.09%)
As of 05/6/2026 12:31 PM Eastern
Compare

GSK - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Hold
Based on 7 Analyst Ratings
Sell
1
Hold
4
Buy
2

Based on 7 Wall Street analysts who have issued ratings for GSK in the last 12 months, the stock has a consensus rating of "Hold." Out of the 7 analysts, 1 has given a sell rating, 4 have given a hold rating, and 2 have given a buy rating for GSK.

Consensus Price Target

GBX 2,034.29
According to the 7 analysts' twelve-month price targets for GSK, the average price target is GBX 2,034.29. The highest price target for GSK is GBX 2,500, while the lowest price target for GSK is GBX 1,500. The average price target represents a forecasted upside of 8.40% from the current price of GBX 1,876.62.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for GSK and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for GSK and its competitors.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

GSK Analyst Ratings Over Time

TypeCurrent Forecast
5/7/25 to 5/7/26		1 Month Ago
4/7/25 to 4/7/26		3 Months Ago
2/6/25 to 2/6/26		1 Year Ago
5/7/24 to 5/7/25
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
2 Buy rating(s)
3 Buy rating(s)
3 Buy rating(s)
5 Buy rating(s)
Hold
4 Hold rating(s)
3 Hold rating(s)
3 Hold rating(s)
1 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
Consensus Price TargetGBX 2,034.29GBX 2,016.43GBX 1,867.86GBX 1,835
Consensus RatingHoldHoldHoldModerate Buy

GSK Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

GSK Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

GSK Stock vs. The Competition

TypeGSKMedical Companies
Consensus Rating Score
2.14
2.30
Consensus RatingHoldHold
News Sentiment Rating
Positive News

See Recent GSK News
Positive News
Export
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside		Details
5/6/2026
Deutsche Bank Aktiengesellschaft logo
Deutsche Bank Aktiengesellschaft
2 of 5 stars
 Reiterated RatingHoldGBX 1,900 ➝ GBX 1,900+1.01%
5/6/2026
Citigroup Inc. logo
Citigroup
4 of 5 stars
 Lower TargetNeutralGBX 2,250 ➝ GBX 2,100+12.06%
4/14/2026
Jefferies Financial Group Inc. logo
Jefferies Financial Group
2 of 5 stars
 Reiterated RatingBuyGBX 2,500 ➝ GBX 2,500+14.94%
3/26/2026
Berenberg Bank logo
Berenberg Bank
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Reiterated RatingHoldGBX 2,000-3.17%
3/25/2026
Shore Capital Group Ltd logo
Shore Capital Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Reiterated RatingBuy
1/23/2026
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Reiterated RatingNeutralGBX 1,940+7.51%
1/7/2026
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Reiterated RatingUnderweight
5/7/2024
Barclays PLC logo
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Reiterated RatingEqual WeightGBX 1,725-1.96%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 03:29 AM ET.


Should I Buy GSK Stock? GSK Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, May 6, 2026. Please send any questions or comments about these GSK pros and cons to contact@marketbeat.com.

GSK
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in GSK plc:

  • The current stock price is around GBX 1,848, which has recently crossed above its 200-day moving average, indicating potential upward momentum.
  • GSK plc has received positive ratings from analysts, with two analysts issuing a "Buy" rating, suggesting confidence in the company's future performance.
  • The company reported a solid earnings per share (EPS) of GBX 55 for the last quarter, reflecting its profitability and operational efficiency.
  • GSK plc has a market capitalization of approximately £74.55 billion, indicating a strong position in the market and the ability to invest in research and development.
  • Recent insider buying activity, with executives purchasing shares, can signal confidence in the company's future prospects and alignment with shareholder interests.

GSK
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in GSK plc for these reasons:

  • The company has a relatively high debt-to-equity ratio of 114.64, which may indicate financial risk and reliance on debt for growth.
  • GSK plc has a current ratio of 0.81, suggesting potential liquidity issues, as it may not have enough short-term assets to cover its short-term liabilities.
  • Analysts have set a consensus price target of GBX 1,762, which is below the current stock price, indicating potential downside risk.
  • One analyst has issued an "underweight" rating, suggesting that the stock may not perform as well as the market or its peers.
  • The company's net margin of 8.02% may be considered low compared to industry standards, indicating less profitability relative to its revenue.

GSK Forecast - Frequently Asked Questions

According to the research reports of 7 Wall Street equities research analysts, the average twelve-month stock price forecast for GSK is GBX 2,034.29, with a high forecast of GBX 2,500 and a low forecast of GBX 1,500.

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for GSK in the last twelve months. There is currently 1 sell rating, 4 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" GSK shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GSK, but not buy additional shares or sell existing shares.

According to analysts, GSK's stock has a predicted upside of 8.40% based on their 12-month stock forecasts.

GSK has been rated by research analysts at Berenberg Bank, Citigroup, Deutsche Bank Aktiengesellschaft, Jefferies Financial Group, and Shore Capital Group in the past 90 days.

Analysts like GSK less than other "medical" companies. The consensus rating score for GSK is 2.14 while the average consensus rating score for "medical" companies is 2.30. Learn more on how GSK compares to other companies.

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With GSK Recommendations


This page (LON:GSK) was last updated on 5/7/2026 by MarketBeat.com Staff.
From Our Partners
The $1.75T "Backdoor" ticker (NOT Starlink)
When the SpaceX IPO launches, most investors will already be too late. The real opportunity isn't the IPO itse...
Behind the Markets | Sponsoredtc pixel
Elon Unveils AI Passive Income Stream for Millions of Americans
During Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...
InvestorPlace | Sponsoredtc pixel
Before you buy SpaceX shares, consider this alternative approach
SpaceX has confidentially filed for an IPO with the SEC, targeting a June 2026 listing at a valuation exceedin...
Weiss Ratings | Sponsoredtc pixel
URGENT: $2 Gold Stock With Major Discovery
A $2 gold stock is said to quietly control what may be the largest gold deposit in the world - worth nearly $1...
Paradigm Press | Sponsoredtc pixel